Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in Vermont: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 293 | 13% |
| 2020 | 4 | 208 | 16% |
| 2021 | 2 | 238 | 22% |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Vermont; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 98 | 8,379−6.8%/yr | −6.8%/yr | 4.6 | 43% | 8,410 in 2030+0.1%/yr |
| New Jersey | 53 | 6,583 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 10 | 397+2.5%/yr | +2.5%/yr | 3.50.6× | 0% | 810 in 2030+13%/yr |
| Hysterectomy, hysteroscopy & ablation |
BPH procedures in every state, and its device makers · Every procedure market in Vermont · Every state · Compare with New York
| 2024 |
| 218 |
| 35% |
| 2025 est. | ≈ 210 | – |
| 2026 est. | ≈ 270 | – |
| 2022 | 4 | 279 | 30% |
| 2023 | 4 | 297 | 33% |
| 2024 | 3 | 218 | 35% |
| 2025 from claims | – | 209 170–246 | 34% |
| 2026 forecast | – | 272 215–344 | 14% |
| 2027 forecast | – | 286 215–382 | 10% |
| 2028 forecast | – | 301 217–419 | 7% |
| 2029 forecast | – | 316 219–458 | 4% |
| 2030 forecast | – | 331 222–498 | 1% |
In 2025, 100% hospital outpatient.
| −1.2%/yr |
| 6.3 |
| 53% |
| 5,790 in 2030−2.1%/yr |
| Pennsylvania | 78 | 5,695−7.3%/yr | −7.3%/yr | 4.2 | 31% | 4,890 in 2030−2.5%/yr |
| Massachusetts | 46 | 2,715−3.3%/yr | −3.3%/yr | 2.9 | 13% | 2,890 in 2030+1.1%/yr |
| Connecticut | 20 | 1,312+0.2%/yr | +0.2%/yr | 3.9 | 19% | 1,290 in 2030−0.3%/yr |
| New Hampshire | 11 | 729−2.6%/yr | −2.6%/yr | 3.2 | 25% | 880 in 2030+3.1%/yr |
| Maine | 6 | 407−1.2%/yr | −1.2%/yr | 2.6 | 0% | 340 in 2030−2.7%/yr |
| Rhode Island | 5 | 341+2.1%/yr | +2.1%/yr | 3.7 | 20% | 270 in 2030−3.6%/yr |
| 4 |
| 185−5.5%/yr |
| −5.5%/yr |
| 1.70.5× |
| 9% |
| 350 in 2030+11%/yr |
Teleflex leads with 97% of company spending on these surgeons in 2025, +72 pts on 2024.
In 2025, 2 companies reported engagement with Vermont’s surgeons worth $1,660 in consulting, speaking, meals and travel tied to these products, about $553 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.